Propanc Biopharma (Propanc Biopharma) Total Assets : $0.04 Mil (As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Propanc Biopharma Total Assets?

Propanc Biopharma's Total Assets for the quarter that ended in Mar. 2024 was $0.04 Mil.

During the past 12 months, Propanc Biopharma's average Total Assets Growth Rate was -39.20% per year. During the past 3 years, the average Total Assets Growth Rate was 16.00% per year. During the past 5 years, the average Total Assets Growth Rate was -5.30% per year. During the past 10 years, the average Total Assets Growth Rate was 5.70% per year.

During the past 13 years, Propanc Biopharma's highest 3-Year average Total Assets Growth Rate was 405.30%. The lowest was -86.60%. And the median was -7.90%.

Total Assets is connected with ROA %. Propanc Biopharma's annualized ROA % for the quarter that ended in Mar. 2024 was -1,511.11%. Total Assets is also linked to Revenue through Asset Turnover. Propanc Biopharma's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Propanc Biopharma Total Assets Historical Data

The historical data trend for Propanc Biopharma's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Propanc Biopharma Total Assets Chart

Propanc Biopharma Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Assets

Get a 7-Day Free Trial

0.10

0.01

0.08

0.06

Propanc Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial															0.14	0.06	0.18	0.24	0.04

Propanc Biopharma Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Propanc Biopharma's Total Assets for the fiscal year that ended in Jun. 2023 is calculated as

Total Assets	=	Total Equity (A: Jun. 2023 )	+	Total Liabilities (A: Jun. 2023 )
	=	-3.117	+	3.178
	=	0.06

Propanc Biopharma's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	-3.7	+	3.737
	=	0.04

Propanc Biopharma (OTCPK:PPCB) Total Assets Explanation

Total Assets is connected with ROA %.

Propanc Biopharma's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-2.108	/	( (0.242	+	0.037)	/ 2 )
	=	-2.108	/	0.1395
	=	-1,511.11 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Propanc Biopharma's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	0	/	( (0.242	+	0.037)	/ 2 )
=	0	/	0.1395
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Propanc Biopharma Total Assets Related Terms

Thank you for viewing the detailed overview of Propanc Biopharma's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Propanc Biopharma (Propanc Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Propanc Biopharma Inc (OTCPK:PPCB) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

302, 6 Butler Street, Cambwerwell, VIC, AUS, 3124

Website

https://www.propanc.com

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

Executives

Josef Zelinger	director	59 SEYMOUR ROAD, ELSTERNWICK C3 3185
Carlo M Campiciano	officer: CFO & Secretary	C/O. PROPANC BIOPHARMA,INC., 302, 6 BUTLER STREET, CAMBERWELL C3 3124
Julian Norman Kenyon	director	BEECHWOOD, EMBLEY LANE, EAST WELLOW, ROMSEY HAMPSHIRE X0 SO516DN
James Andrew Nathanielsz	director, officer: CEO, CFO, Secretary, Treasurer	1/76 SUMMERHILL ROAD, GLEN IRIS, VICTORIA C3 3146